Post-Brexit, MAA submissions, medicinal products

Types of MAA in the UK after Brexit

There are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotland and Wales) or Northern Ireland. Each of them would reflect in obtaining a specific MA number:

UK PL (New National Applications)
GB PL (National procedures, Reliance Procedure)
NI PL (NI national MA, CAP and DCP/MRP as CMS)

The options available will be determined by the intended market and the type of application. You need to follow a specific application procedure depending on the licence (marketing authorisation) you need. To obtain a medical product authorization, you need to use one of the following procedures:

National Routes
International routes (collaborative procedures)

Below you could find a list of available application types and references to the MHRA guidelines.

National procedures

Innovative Licensing and Access Procedure (ILAP) – only for the innovative medicines, including new chemical entities, and biological medicines, new indications and repurposed medicines.
National Procedure (a 150-day procedure) only for high-quality applications to market a medicine in the United Kingdom, Great Britain or Northern Ireland
Rolling review – modules submission authorisation in the UK, GB and NI
EC Decision Reliance Procedure (a 67-day procedure) – for EU CAP authorized products parallel application in GB (CAP would include NI).
MR/DC Reliance Procedure (a 67-day procedure) – for EU DCP and MRPs approved products for GB.
Unfettered Access from Northern Ireland (a 67-day procedure) - recognition in GB of a marketing authorisation approved in NI under certain qualifying conditions.

International routes (collaborative procedures)

Access consortium - if you want to market a medicine in the UK, Australia, Canada, Singapore and/or Switzerland.
Project Orbis – Project Orbis is a programme coordinated by the US Food and Drug Administration (FDA), involving the regulatory authorities of Australia (TGA), Canada (Health Canada), the United Kingdom (MHRA), Singapore (HSA) and Brazil (ANVISA) to review and approve promising cancer treatments.
Northern Ireland may be included in decentralised or mutual recognition procedure as a Concerned Member State (CMS)
Also, Marketing authorisations approved in the European Union centralised procedure will automatically affect Northern Ireland.

Applications can be fast-tracked if there is compelling evidence of benefit in a public health emergency or if there is a shortage of supply of an essential medicine that has been verified by the Department of Health and Social Care (DHSC).

Types of application (legal basis)

You must include the appropriate legal basis for your application when you apply to the MHRA for a marketing authorisation:

Full application (previously Article 8(3) of Directive 2001/83/EC)-> Regulation 50
Generic application (previously Article 10.1) -> Regulation 51
Hybrid application (previously Article 10.3) -> Regulation 52
Similar biological application (previously Article 10.4) -> Regulation 53
Well-established use application (previously Article 10a) -> Regulation 54
Fixed-combination application (previously Article 10b) – Regulation 55
Informed consent application - Regulation 56 (previously Article 10c)
Traditional herbal registrations – Regulation 125 & 126 (previously Article 16a)
Certificate of homoeopathic medicinal products - Regulation 102 (previously Article 14(1))
National homeopathic products - Regulation 50(6)(g) and Schedule 10 (previously Article 16(2))

Application process highlights

A dossier should be submitted in eCTD or NeeS format
ASMF must be submitted either before you submit your application or at the same time
Procedures concerning the use of Certificates of Suitability (CEPs) will remain the same
Get a PL number (for a UK, Great Britain or Northern Ireland licence) from the MHRA Portal or by emailing PLNumberAllocation@mhra.gov.uk before you submit your application.
All applications should be submitted through the MHRA Submissions Portal.
The SmPC should be submitted in the correct SmPC template

Important notice: Products in the UK are expected to meet the standards published by the BP. BP continues to reproduce European Pharmacopoeia text.

More detailed info: https://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk or on our website https://brexit.freyrsolutions.com/

What our Clients Say?

We have had a good impression of Freyr and feel more than comfortable telling our partners that we are engaging with Freyr for our Regulatory needs. The project went very smoothly, and at a reasonable pace. The team was knowledgeable, friendly and accommodating. Rapid response appreciated. Keep up the good work.

Director, Regulatory Affairs,

US based leading precision medicine company

Speed of service, responsiveness, attention to our needs, quality of product, and price are all very important and I felt they were very good in our work with Freyr. Service was delivered appropriately and in a timely fashion. Thankful to Freyr’s responsive team because of which we could comprehend our unusual needs. I thought the support was very good and met with expectations. In addition, found the price reasonable given the workload.

Director, Regulatory Affairs,

US based leading precision medicine company

You have exceeded our expectations as a team and individuals! Special thanks for all the prepared technical documentation!! What an effort team! Again, many thanks for all the work and efforts put into this, moving forward positively. Thank you for your consistency, perseverance, and amazing teamwork at Freyr. we would like to express our gratitude to the Freyr team for all the great work and expertise that they have brought to the project to make it a success!

Regulatory Affairs Officer

A Global Industry Leader in Medical Device Design and Manufacturing

Thank you so much Freyr team for your support on the way in registering 3 of our medical devices in Philippines.
I hope this achievement will open numerous business opportunities for both Freyr and our company to work in synergy.

Associate, Regulatory Affairs Team II,

Clinical & Regulatory Affairs Center,
A Korean Chemical Company

Thank you very much for the support. A regulatory requirement to submit a safety report and obtain an accession number was a totally new process for us and we had plenty of doubts especially when having strong comments from other internal departments.
Freyr has successfully obtained the accession number within a short timeline. That’s what is really important and gratifying. Thank you again and keep up the excellent work!

Manager, Regulatory Affairs

A Spanish Medical Devices Manufacturer

The team has always been very professional and supportive with our projects and inquiries. Communication was always timely. Knowledge of regulations, open communication, timely follow ups with my team and professionalism. What I wanted to add as a strength yet did not; was the ability to work without sleep. I feel you all work around the clock as you are very responsive on our questions any time of day ?

Director, Regulatory Affairs

US based top Sterilization company

Types of MAA in the UK after Brexit

National procedures

International routes (collaborative procedures)